TSXV:VXL

Stock Analysis Report

Executive Summary

Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Vaxil Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

VXL

0.6%

CA Biotechs

0.1%

CA Market


1 Year Return

-45.5%

VXL

-18.5%

CA Biotechs

1.6%

CA Market

Return vs Industry: VXL underperformed the Canadian Biotechs industry which returned -18.5% over the past year.

Return vs Market: VXL underperformed the Canadian Market which returned 1.6% over the past year.


Shareholder returns

VXLIndustryMarket
7 Day0%0.6%0.1%
30 Day0%-13.9%-2.9%
90 Day-25.0%-17.0%-1.4%
1 Year-45.5%-45.5%-18.5%-18.5%5.2%1.6%
3 Year-77.8%-77.8%-17.7%-17.7%13.8%3.7%
5 Yearn/a13.5%13.5%25.3%7.2%

Price Volatility Vs. Market

How volatile is Vaxil Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vaxil Bio undervalued compared to its fair value and its price relative to the market?

43.04x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate VXL's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate VXL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VXL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: VXL is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate VXL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VXL is overvalued based on its PB Ratio (43x) compared to the CA Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Vaxil Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vaxil Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Vaxil Bio performed over the past 5 years?

8.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VXL is unprofitable, but has reduced losses over the past 5 years at a rate of 8.2% per year.

Accelerating Growth: Unable to compare VXL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VXL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: VXL has a negative Return on Equity (-1746.77%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: VXL is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: VXL is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Vaxil Bio's financial position?


Financial Position Analysis

Short Term Liabilities: VXL's short term assets (CA$392.0K) exceeds its short term liabilities (CA$365.0K)

Long Term Liabilities: VXL has no long term liabilities


Debt to Equity History and Analysis

Debt Level: VXL is debt free.

Reducing Debt: VXL currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: VXL has a low level of unsold assets or inventory.

Debt Coverage by Assets: VXL's debt is not covered by short term assets (assets are -5.4x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VXL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VXL has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.9% each year.


Next Steps

Dividend

What is Vaxil Bio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VXL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VXL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VXL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VXL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VXL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Vaxil Bio's salary, the management and board of directors tenure and is there insider trading?

2.4yrs

Average board tenure


CEO

David Goren 0

1.1yrs

Tenure

CA$128,000

Compensation

Mr. David Goren has been Chief Executive Officer of Vaxil Bio Ltd. since September 2018 and has been its Chairman since August 2019. He also serves as Director of Vaxil Bio Ltd. Since September 04, 2018. M ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether David's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.


Board Age and Tenure

2.4yrs

Average Tenure

46yo

Average Age

Experienced Board: VXL's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Gadi Levin (46yo)

    CFO & Director

    • Tenure: 3yrs
    • Compensation: CA$59.00k
  • Isaac Maresky (28yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: CA$155.00k
  • Riva Kovjazin

    Senior Scientist & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • David Goren

    Chairman

    • Tenure: 1.1yrs
    • Compensation: CA$128.00k

Board Members

  • Gadi Levin (46yo)

    CFO & Director

    • Tenure: 3yrs
    • Compensation: CA$59.00k
  • Isaac Maresky (28yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: CA$155.00k
  • Ari Kellen (56yo)

    Director & Member of Scientific Advisory Board

    • Tenure: 1.8yrs
  • Riva Kovjazin

    Senior Scientist & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Shawn Langer

    Director & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • David Goren

    Chairman

    • Tenure: 1.1yrs
    • Compensation: CA$128.00k

Company Information

Vaxil Bio Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vaxil Bio Ltd.
  • Ticker: VXL
  • Exchange: TSXV
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$2.668m
  • Shares outstanding: 88.93m
  • Website: https://vxlbio.com

Location

  • Vaxil Bio Ltd.
  • 3400 One First Canadian Place
  • Toronto
  • Ontario
  • M5X 1A4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VXLTSXV (TSX Venture Exchange)YesCommon SharesCACADMar 2016
VXLL.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2016

Biography

Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel. The company’s lead product is ImMucin that has com ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:02
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.